Your browser doesn't support javascript.
loading
Aberrant activation of RPB1 is critical for cell overgrowth in acute myeloid leukemia.
Yu, Qingfeng; Xu, Ying; Zhuang, Haifeng; Wu, Zhaoxing; Zhang, Lei; Li, Jinfan; Yang, Linlin; Wu, Bowen; Wang, Ping; Zhang, Xuzhao; Gan, Xiaoxian; Liang, Yun; Zheng, Shu; Yu, Xiaofang; Gu, Ying; Xu, Rongzhen.
Afiliação
  • Yu Q; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China; Department of Hematology, the First Affiliated Hospital of Zh
  • Xu Y; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China.
  • Zhuang H; Department of Hematology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310009, China.
  • Wu Z; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China.
  • Zhang L; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China.
  • Li J; Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
  • Yang L; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China.
  • Wu B; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China.
  • Wang P; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China.
  • Zhang X; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China.
  • Gan X; Zhejiang Academy of Medical Sciences, Hangzhou, 310012, China.
  • Liang Y; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China.
  • Zheng S; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China.
  • Yu X; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China; Department of Hematology, the First Affiliated Hospital of Zh
  • Gu Y; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China; Institute of Genetics, Zhejiang University and Department of
  • Xu R; Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China; Institute of Hematology, Zhejiang University, Hangzhou, 31000
Exp Cell Res ; 384(2): 111653, 2019 11 15.
Article em En | MEDLINE | ID: mdl-31574286
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA Polimerase II / Leucemia Mieloide Aguda / Proliferação de Células Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans Idioma: En Revista: Exp Cell Res Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA Polimerase II / Leucemia Mieloide Aguda / Proliferação de Células Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Female / Humans Idioma: En Revista: Exp Cell Res Ano de publicação: 2019 Tipo de documento: Article